Ignite Creation Date:
2024-05-05 @ 11:50 AM
Last Modification Date:
2024-10-26 @ 9:15 AM
Study NCT ID:
NCT00156780
Status:
COMPLETED
Last Update Posted:
2006-10-23
First Post:
2005-09-08
Brief Title:
Phase 1 Safety and Pharmacokinetic Study of AI-700 in Patients With Diminished DLCO and COPD andor CHF
Sponsor:
Acusphere
Organization:
Acusphere
Study Overview
Official Title:
A Phase 1 Double Blind Crossover Placebo-Controlled Dual-Injection Safety and Pharmacokinetic Study of AI-700 in Patients With Diminished DLCO and Chronic Obstructive Pulmonary Disease COPD andor Congestive Heart Failure CHF
Status:
COMPLETED
Status Verified Date:
2006-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study was conducted to evaluate the safety and pharmacokinetics of an echocardiographic contrast agent AI-700 in patients with moderate to severe chronic obstructive pulmonary disease COPD andor congestive heart failure CHF
Detailed Description:
In ongoing clinical trials AI-700 is currently being evaluated for its value to provide enhanced echocardiography to detect CAD The patient population is comprised of those patients who have chest pain and are being evaluated for inducible ischemia This population may include patients with compromised pulmonary function due to COPD or CHF This study was to evaluate the safety of AI-700 in these patients
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None